Current Appointments
General Hospital Pula
Vice Chair Hospital, Quality Management and Head of Department of
Oncology and Hematology
Negri 6, 52100 Pula, Croatia
October 2016-present
University of Pula
Postgraduate Nursing Study of Biomedicine and Health
Assist.profess. and Research Associate
Zagrebačka 30, 52100 Pula, Croatia
June 2016-present
University of Rijeka
Medical School Rijeka
Assist.profess.
Department of Internal Medicine
B.Branchetta 20, 51000 Rijeka, Croatia
December 2015-present
Education
2009 – 2010 Subspecialisation
Medical Oncology Clinical Hospital Rijeka,
Krešimirova 421, 51000 Rijeka, Croati
2003 – 2009 PhD Doctor of Philosophy
University of Rijeka, Medical School
Trg braće Mažuranića 10, 51000 Rijeka, Croatia
2003 – 2007 Resident Internal Medicine
Clinical Hospital Rijeka,
Krešimirova 42, 51000 Rijeka, Croatia
1999 – 2003 Msc Master of Science
University of Rijeka, Medical School
Trg braće Mažuranića 10, 51000 Rijeka, Croatia
1987 – 1993 MD Doctor of Medicine
University of Zagreb, Medical School,
Šalata 3, 10000 Zagreb, Croatia
Training
2017 The Royal College of Physicians
Oncology at the limits, Lancet Oncology Educational Program
11 St Andrews Place, Regent’s Park
London NW1 4LE, United Kingdom
2011 Cicely Saunders Institute,
Palliative Care Education
Bessemer Road,
London SE5 9PJ, United Kingdom
2009 St. Christopher Hospice, London
Palliative Care Education
51-59 Lawrie Park Road, Sydenham
London, SE26 6DZ, United Kingdom
2006 Weil-Cornell by Memorial Sloan Kettering Cancer Center
Hematology education
Salzburg, Austria
2005 Cleveland Clinical Hospital Observership
Taussig Cancer Centre, Hematology Department
Mentored by Alan Lichtin
10524 Euclid Ave. Cleveland, OH 44195
Professional Experience
2016-present Vice Chair Hospital, Quality Management
General Hospital Pula
Negri 6, 52100 Pula, Croatia
2012-present Head of Department of Oncology and Hematology
General Hospital Pula
Negri 6, 52100 Pula, Croatia
2013-2016 Head of Department of Internal Medicine
General Hospital Pula
Negri 6, 52100 Pula, Croatia
2012-2013 Hospital Board Member
General Hospital Pula
Negri 6, 52100 Pula, Croatia
2007-2012 Internist, Oncologist
General Hospital Pula
Department of Internal Medicine
Negri 6, 52100 Pula, Croatia
2005-2007 Resident Internal Medicine
Clinical Hospital Rijeka
Krešimirova 42, 51000 Rijeka, Croatia
2003-2005 Resident Internal Medicine
General Hospital Pula
Department of Internal Medicine
Negri 6, 52100 Pula, Croatia
2000-2003 Doctor of Medicine
General Hospital Pula
Department of Internal Medicine
Negri 6, 52100 Pula, Croatia
1997-2003 Doctor of Medicine
Surgical Policlinic St Pellegrin
Stella Maris, 52470, Umag, Croatia
Licensure & Certification
Croatian Medical Chamber
Board Certification 2015-present
Licence No. 10434
Association of Clinical Research Certification
GCP certificate 2018 -present
Awards and Honors
2018 Adris Foundation award
2016 Croatian Cancer League, Istria Award 50 years
Professional Associations
2009-present American Society of Medical Oncology
Full Member ID 87601
2017-present Croatian Society for Quality Improvement in Health Care
2009-present Croatian Association of Clinical Oncology
2000-present Croatian Medical Chamber and Croatian Medical Association
REASEARCH ACTIVITIES
Current non-profit studies
2018-present Patient reported outcomes project
2016-present Pepsinogen in Early Detection of Gastric Cancer
(EudraCT number 2016-000519-34 has been issued for your Sponsor’s Protocol Code Number 1068).
2016-present Erectile Dysfunction in Patients with Prostate Cancer
2015-present Web page: www.cancerevolution.net
Editorial Boards
2009-present Glasnik Pulske Bolnice (Journal of General Hospital Pula)
PUBLICATIONS
Manuscripts
Herceg D, Jakopović M, Trivanovic D et al. Cancer patients follow-up croatian society for medical oncology clinical guidelines part v: melanoma, sarcomas, central nerve system tumors, lung cancer. Lijec Vjesn 2017;139:17–23. Šeparović R, Silovski T, Trivanović D et al. Cancer patients follow-up croatian society of medical oncology clinical guidelines part i: breast cancer, uterine cancer, cervical cancer, ovarian cancer. Lijec Vjesn 2016;138:63–68. Bišof V, Juretić A, Trivanović D et al. Clinical recommendations for diagnosis, treatment and monitoring of patients with cancer of unknown primary site. Lijec Vjesn. 2015;137:65-9. Dobrila-Dintinjana R, Trivanovic D, Zelic M, Radic M, Dintinjana M, Petranovic D, Toni V, Vukelic J, Matijasic N. Nutritional Support in Patients with Colorectal Cancer during Chemotherapy: Does it Work? Hepatogastroenterology. 2013;60:475-80. Trivanović D, Petković M, Štimac D. New Prognostic Index to Predict Survival in Patients with Cancer of Unknown Primary Site with Unfavourable Prognosis Clinical Oncology. 2009;21:43-48. Trivanović D, Petković M, Štimac D. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Cancer. 2007;109:2623-4.Publications as contributor in Clinical trials Paz-Ares L, Mezger J, Ciuleanu TE et al. INSPIRE investigators (Trivanovic D.). Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. Lancet Oncol. 2015;16:328-37. Fuchs CS et al. (Trivanovic D.) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31-9. (contr.) Lang I, Brodowicz T, Ryvo L et al.Central European Cooperative Oncology Group Investigators (Trivanovic D.). Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open- label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol. 2013;14:125-33.(contr.) Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG; SAVE-ONCO Investigators (Trivanovic D.). Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med. 2012;366:601-9.
Abstracts (selected international)
Trivanovic D, Hrstic I, Budisavljevic A et al. Patient related outcomes in cancer patients in Croatia. J Clin Oncol 37, 2019 (suppl; abstr TPS6650)
Trivanovic D, Plestina S. Honovic L et al. Final results of early non-invasive gastric cancer detection study using the serum pepsinogen test method in Croatian patients. J Clin Oncol 37, 2019 (suppl; abstr e15551)
Trivanovic, L. Honovic, J. Vlasic, I. Hrstic. Early non-invasive
detection of gastric cancer with plasma pepsinogens in Croatian patients.
ESMO Annual Congress Kopenhagen, 2016.
Trivanovic D, Kocic L, Dembic M, Spasic N, Budisavljevic A. Prognostic Factors Associated with Overall Survival in Croatian Patients with Advanced Lung Cancer 16th World Conference on Lung Cancer, Denver, Colorado, USA 2015. Vrdoljak E, Soldic Z, Gasparic M, Boskovic L, Belac Lovasic I, Dabelic N, Gugic D, Ledina D, Bozic Sakic M, Raspovic Z, Zorica R, Trivanovic D, Petkovic M Optimization of breast cancer patients’ follow-up – potential way to improve cancer care in transition countries. ESMO Annual Congress Vienna 2015.
Trivanovic D, Spasic N, Plestina S, Dobrila-Dintinjana R, Kocic L. Impact of complementary and alternative medicine (CAM), religiosity, and evidence-based medicine (EBM) in advanced cancer patients. Clin Oncol
32, 2014 (suppl; abstr e12000) ASCO Annual Congress, Chicago, IL 2014.
Trivanovic D, Spasić N, Pleština S et al. Chemobrain in patients
participating in clinical trials. ESMO Annual Congress 2013.Amsterdam.
Trivanovic D, Plestina S, Dobrila-Dintinjana R, Honovic L, Jerin L, Hrstic I. Vitamin D3 supplementation to improve fatigue in patients with advanced cancer.J Clin Oncol 30, 2012 (suppl; abstr 9097). Chicago ASCO 2012. Trivanovic D., Plestina S., Jerin L., Honovic L. An open-label randomized phase II trial of oral vitamin D3 supplementation in combination with standard chemotherapy or best supportive care compared with standard chemotherapy and best supportive care in patients with advanced solid tumors. J Clin Oncol 29: 2011 (suppl; abstr e19566). Chicago ASCO 2011.
Trivanović D, Petković M, Dobrila Dintinjana R, Mavrić Ž, Štimac D. QTc interval in advanced cancer patients. J Clin Oncol;27: 2009. (suppl;abstr e20658). Orlando ASCO 2009.
Trivanović D. Interactive case report. Reply to Sodeck et al. BMJ 326 : 974 doi: 10.1136/bmj.326.7396.974 (Published online 3 May 2003).
Book Chapters
Beslija, Vrbanec et al. Medical Oncology, 2nd edition 2019. In press.
Balenović A et al. Trivanović D. Kliničke Onkološke Studije u PET/CT Klinička primjena. Hazu Zagreb 2015.
Trivanović D. Dobrila Dintinjana R. Onkološki pristup tumorima jetre hepatobilijarnih puteva. Medix, Zagreb 2013.
Dobrila-Dintinjana R, Trivanović D et al. Effects of Dietary Counseling on
Patients with Colorectal Cancer. Colorectal cancer in book: From prevention
To patient care Edited by Rajunor Ettarh. Intech 2012.
Dissertations
Trivanovic D. Diagnostic and Prognostic Factors in Patients with Cancer of
Unknown Primary Site. University of Rijeka: Rijeka, Croatia 2009. (PhD
dissertation).
Invited Talks/presentations
Trivanovic D. Clinical Importance of Tumor Heterogeneity. HLZ, Pula 2017.
Trivanovic D, Bermanec S, Brumini D. Analiza smrtnosti palijativnih bolesnika u
OB Pula i ŽB Čakovec. 2.Kongres palijativne skrbi Pula 2016
Trivanovic D. Tumor Heterogeneity. 3.kongres hrvatskog društva za
internističku onkologiju HLZ-a. Zagreb 2015.
Trivanović D. Patient with metastatic gastroesophageal junction cancer
(durable response on 2nd line therapy with ramucirumab). 5.HDIO Zagreb 2013.
Trivanović D. Chemotherapy of Liver Tumours. 1st IASGO CME Croatia
course Rovinj 2013.
Clinicial trials:
| Year | 2008. |
| Study | A Multinational, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and who are Undergoing ChemotherapyProtocol Number: EFC6521 – SAVE-ONCO |
| Principal Investigator |
| Year | 2009. |
| Study | A multinational, Randomized, Double-blind Study Comparing the Efficacy and Safety of Aflibercept versus Placebo Administered every 3 weeks in Patients Treated with Docetaxel / Prednisone for Metastatic Androgen-Independent Prostate CancerProtocol Number: EFC6546-VENICE |
| Principal Investigator |
–
| Year | 2010. |
| Study | A Randomized, Multi-Center, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus IMC-11F8 Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Squamous Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Protocol Number: IMCL CP11-0806 |
| Principal Investigator |
| Year | 2010. |
| Study | A Randomized, Multi-Center, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy Plus IMC-11F8 Versus Pemetrexed-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Nonsquamous Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) Protocol Number: IMCL CP11-0805 |
| Principal Investigator |
| Year | 2010. |
| Study | A randomised, multicentre, multinational Phase II study to evaluate pertuzumab in combination with trastuzumab given either concomitantly or sequentially with standard anthracycline based chemotherapy or concomitantly with a non-anthracycline based chemotherapy regimen, as neoadjuvant therapy for patients with locally advanced, inflammatory or early stage HER2-positive breast cancerProtocol Number: BO22280 Tryphaena |
| Principal Investigator |
| Year | 2011. |
| Study | A Randomized, Phase IIb/III Study Of Ganetespib (Sta-9090) in Combination with Docetaxel versus Docetaxel Alone in Subjects With Stage Iiib or IvNon-Small-Cell Lung Cancer Protocol Number: 9090-08 |
| Principal Investigator |
| Year | 2011. |
| Study | A Phase 3, Randomized, Double-Blinded Study of IMC-1121B andBest Supportive Care (BSC) Versus Placebo and BSC in the Treatmentof Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaFollowing Disease Progression on First-Line Platinum- orFluoropyrimidine-Containing Combination Therapy Protocol Number: IMCL CP12-0715 REGARD |
| Principal Investigator |
| Year | 2011. |
| Study | A Phase 3, Multicenter, Randomized, Open Label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With ChemorefractoryWild-Type KRAS Metastatic Colorectal Cancer Protocol Number: AMGEN 20100007 |
| Principal Investigator |
| Year | 2012. |
| Study | Multiple, Fixed-Dose, Comparative Efficacy and Safety Evaluation Of Rgb-02 and Neulasta® In Patients Undergoing Chemotherapy Treatment Known to Induce NeutropeniaProtocol Number: RGB-02-101 |
| Principal Investigator |
| Year | 2012. |
| Study | A randomized phase III 2-arm trial of paclitaxel plus bevacizumab vs. capecitabine plus bevacizumab for the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer Protocol Number: CECOG/BC 1.3.005 |
| Principal Investigator |
| Year | 2012. |
| Study | Phase Iii, Randomized, Double Blind, Placebo-Controlled Study of Vemurafenib(Ro5185426) Adjuvant Therapy In Patients with Surgically Resected, Cutaneous Braf-Mutant Melanoma At High Risk For RecurrenceProtocol Number GO27826 |
| Principal Investigator |
| Year | 2013. |
| Study | A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMab) in Combination with Tarceva ® (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Lung Cancer (NSCLC) who have Received Standard Chemotherapy forAdvanced or Metastatic Disease Protocol Number: OAM4971g |
| Principal Investigator |
| Year | 2014. |
| Study | A Randomized, Phase 3 Study of Ganetespib in Combination with Docetaxel versus Docetaxel alone in Patients with Advanced Non- Small-Cell Lung AdenocarcinomaProtocol Number: 9090-14 |
| Principal Investigator |
| Year | 2014. |
| Study | A Phase 3 Randomized, Double-Blind Study of Pf-06439535 PlusPaclitaxel-Carboplatin and Bevacizumab Plus Paclitaxel-Carboplatin For The First-Line Treatment of Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Protocol Number: B7391003 |
| Principal Investigator |
| Year | 2014, |
| Study | Randomized, Double-Blind, Multicenter, Phase 3 Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin andPaclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Protocol Number: M11-089 |
| Principal Investigator |
| Year | 2016. |
| Study | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study ofPEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab-Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Protocol Number: HALO 109-301 |
| Glavni ispitivač |
| Year | 2017. |
| Study | A multicenter, randomized, double-blind Phase III trial to evaluateefficacy and safety of BI 695502 plus chemotherapy versus Avastin®plus chemotherapy in patients with advanced nonsquamous Non-SmallCell Lung CancerProtocol Number: BI695502 |
| Principal Investigator |
| Current clinical trials |
| YearStudy | 2019,A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC)Protocol Number: ANAM 17-21 |
| Principal Investigator | |
| YearStudy | 2019,ALRN-6924-1-03, Protocol A Phase 1b/2 Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Topotecan-induced Myelosuppression During Treatment forSmall Cell Lung Cancer,Protocol Number: ALRN-6924-1-03 |
| Principal Investigator | |
| YearStudy | 2019,A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIGTM) Versus Alectinib (ALECENSA®) in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI®)Protocol Number: Brigatinib – 30001. |
| Principal Investigator | |
| YearStudy | 2019,A Real World Evidence Prospective Cohort Study in the Management of Metastatic Colorectal Cancer: A Clinical and Patient Perspective(PROMETCO)Protocol Number: PROMETCO |
| Principal Investigator | |
| YearStudy | Phase 2 Study of PD-1 lnhibitor iTX-4014 Alone and in Combination withVopratelimab, an ICOS Agonist, in Biomarker-selected Subjects with Metastatic NSCLC After One Prior Platinum-containing RegimenProtocol Number: JTX-40L4-202 SELECT |
| Principal Investigator |